Experience of use of angioprotectors in the therapy of fetal growth retardation syndrome

Abstract

Aim. The objective of our work was to analyze the pharmacological correction of fetal growth retardation syndrome by monotherapy with diosmin and dipyridamole, and to compare their effectiveness. Materials and methods. A retrospective and prospective examination of 160 pregnant women with a single pregnancy at a gestational age of 28 to 36 weeks with a confirmed diagnosis of fetal growth retardation syndrome of 1 or 2 degrees of an asymmetric form was carried out. An extended collection and analysis of anamnesis, general clinical and obstetric-gynecological examination, laboratory and ultrasound methods were carried out. Newborns were assessed on the Apgar score at birth and 5 minutes later. In the early neonatal period, congenital and transient pathological syndromes were evaluated. Results. In the group where patients received diosmin, not a single case of placentomegaly was detected, there were no congestion in the intervillous space, which improved microcirculation processes in the fetoplacental complex. A positive effect of diosmin on the intrauterine state of the fetus was revealed, which is realized in the form of an increase in its compensatory abilities to adapt to chronic hypoxia in a much larger percentage of cases compared to dipyridamole. Conclusion. The data obtained demonstrate a difference in the pharmacokinetics of these drugs: diosmin equally improves both maternal and fetal blood flow, which is most valuable for fetal growth retardation syndrome, while dipyridamole affects only the uterine blood flow.